Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity. Biomedical Science and Engineering, [S. l.], v. 2, n. 1, 2021. DOI: 10.4081/bse.164. Disponível em: https://materials.pagepress.net/bse/article/view/164. Acesso em: 4 jun. 2026.